Kumud Kalia sold $3.8M of GH
Chief Information Officer at Guardant Health, Inc.. 40,000 shares at an average of $95.32, traded Mar 4, 2026, filed Mar 5, 2026.
Score components
- +15RoleOfficer
- +25Trade size$3.8M at market
- +20Share of holdings soldSold 52% of holdings
- +15Cluster4 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001927831-26-000004, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 4, 2026 | MOption exercise Common Stock | +2,119 | $47.20 | $100k | 36,643 | Mar 5, 2026 |
| Mar 4, 2026 | MOption exercise Common Stock | +15,000 | $47.20 | $708k | 51,643 | Mar 5, 2026 |
| Mar 4, 2026 | MOption exercise Common Stock | +1,000 | $74.00 | $74k | 52,643 | Mar 5, 2026 |
| Mar 4, 2026 | MOption exercise Common Stock | +5,000 | $32.86 | $164k | 57,643 | Mar 5, 2026 |
| Mar 4, 2026 | MOption exercise Common Stock | +10,000 | $28.37 | $284k | 67,643 | Mar 5, 2026 |
| Mar 4, 2026 | MOption exercise Common Stock | +10,000 | $28.61 | $286k | 77,643 | Mar 5, 2026 |
| Mar 4, 2026 | SOpen-market sale Common Stock | -26,980 | $95.12 | $2.6M | 50,663 | Mar 5, 2026 |
| Mar 4, 2026 | SOpen-market sale Common Stock | -13,020 | $95.73 | $1.2M | 37,643 | Mar 5, 2026 |
| Mar 4, 2026 | MOption exercise Stock Option (Right to Buy)derivative | -2,119 | $0.00 | $0 | 49,305 | Mar 5, 2026 |
| Mar 4, 2026 | MOption exercise Stock Option (Right to Buy)derivative | -15,000 | $0.00 | $0 | 34,305 | Mar 5, 2026 |
| Mar 4, 2026 | MOption exercise Stock Option (Right to Buy)derivative | -1,000 | $0.00 | $0 | 27,670 | Mar 5, 2026 |
| Mar 4, 2026 | MOption exercise Stock Option (Right to Buy)derivative | -5,000 | $0.00 | $0 | 6,414 | Mar 5, 2026 |
| Mar 4, 2026 | MOption exercise Stock Option (Right to Buy)derivative | -10,000 | $0.00 | $0 | 9,410 | Mar 5, 2026 |
| Mar 4, 2026 | MOption exercise Stock Option (Right to Buy)derivative | -10,000 | $0.00 | $0 | 25,721 | Mar 5, 2026 |
Related signals
Other insiders at Guardant Health, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 41Moderate | Guardant Health, Inc. | Alex M Azar II director | $145k 826 shares | -50% | |
| 55Moderate | Guardant Health, Inc. | Darya Chudova Chief Technology Officer | $1.4M 7,738 shares | -10% | |
| 65Notable | Guardant Health, Inc. | Steve E. Krognes director | $1.2M 6,674 shares | -46% | |
| 0Weak | Guardant Health, Inc. | Musa Tariq director | $20k 116 shares | -1% | |
| 50Moderate | Guardant Health, Inc. | Kumud Kalia Chief Information Officer | $632k 4,000 shares | -9% | |
| 35Weak | GHsell Guardant Health, Inc. | Michael Brian Bell Chief Financial Officer | $257k 2,000 shares | -4% | |
| 56Moderate | GHsell Guardant Health, Inc. | Ian T Clark director | $735k 6,876 shares | -70% | |
| 15Weak | Guardant Health, Inc. | Musa Tariq director | $31k 348 shares | -4% | |
| 35Weak | Guardant Health, Inc. | Michael Brian Bell Chief Financial Officer | $261k 3,000 shares | -6% | |
| 45Moderate | Guardant Health, Inc. | Medina Manuel Hidalgo director | $119k 1,300 shares | -52% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.